EpimAb Biotherapeutics
PrivateLast Round
IPO
Dec 18, 2025
Est. Valuation
$492.3M
Total Funding Raised
$264.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
EpimAb Biotherapeutics is a biopharmaceutical company specializing in the research and development of innovative bispecific antibody therapeutics using its proprietary FIT-Ig technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Platform-as-a-Service
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EpimAb Biotherapeutics Comparables
Compare EpimAb Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Elpiscience Biopharmaceuticals | 85% | |
| Invenra | 82% | |
| Suzhou Alphamab Co., Ltd. | 82% |
EpimAb Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Dec 18, 2025 | ||||
| Convertible Debt | Apr 25, 2022 | ||||
| Series C | Mar 22, 2021 | ||||
| Series B Extension | Mar 11, 2020 | ||||
| Series B | Jun 5, 2019 | ||||
Series A | Apr 25, 2017 |
Key People
Founding team and executive leadership
EpimAb Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SDIC Fund Management | Series C |
| SCVC | Series B |
| Yanchuang Capital | Series C |
| Mirae Asset | Series C |
| 招银国际金融有限公司 | IPO, Series C |
| Bencao Capital | Series A, Series B |
| CITIC Securities | IPO |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 17, 2026
Presenting novel prodrug T-cell engager platform at AACR Annual Meeting.
- Feb 10, 2026
Partner Almirall filed CTA for bispecific antibody technology.
EpimAb Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about EpimAb Biotherapeutics's valuation, stock price, and market status.
Is EpimAb Biotherapeutics a public or private company?
EpimAb Biotherapeutics is a private company.
What is the current stock price of EpimAb Biotherapeutics?
EpimAb Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks EpimAb Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EpimAb Biotherapeutics worth (valuation)?
EpimAb Biotherapeutics's valuation is estimated at $492.3M based on funding round data.
Can I buy EpimAb Biotherapeutics stock?
EpimAb Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EpimAb Biotherapeutics's last funding round?
EpimAb Biotherapeutics's most recent funding round was IPO on December 18, 2025.
Who are the main investors in EpimAb Biotherapeutics?
Key investors in EpimAb Biotherapeutics include Mirae Asset, 招银国际金融有限公司, CITIC Securities, SDIC Innovation Investment Management, Oriza Seed Venture Capital.
Will EpimAb Biotherapeutics IPO soon?
No public IPO plans have been announced for EpimAb Biotherapeutics.
How can I track EpimAb Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in EpimAb Biotherapeutics's shares on secondary markets.